6-K 1 ea0249336-6k_ascentage.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2025

 

Commission File Number: 002-023311

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒            Form 40-F ☐

 

 

 

 

 

 

On July 17, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

 

1

 

 

INDEX TO EXHIBITS

 

Exhibit
Number 		   Exhibit Title
99.1   Press Release dated July 17, 2025

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  ASCENTAGE PHARMA GROUP INTERNATIONAL
   
Date: July 17, 2025 /s/ Dajun Yang
  Name:  Dajun Yang
  Title: Chief Executive Officer

 

 

3